Cargando…
Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
INTRODUCTION: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. MATERIALS AND METHODS: 3-(4,5-Dimethylthiazol-2yl)-2,5...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052925/ https://www.ncbi.nlm.nih.gov/pubmed/30038488 http://dx.doi.org/10.2147/DDDT.S163595 |
_version_ | 1783340747051761664 |
---|---|
author | Huang, Jianfeng Yuan, Xiaopeng Pang, Qingfeng Zhang, Haowen Yu, Jiahua Yang, Bo Zhou, Leyuan Zhang, Fuzheng Liu, Fenju |
author_facet | Huang, Jianfeng Yuan, Xiaopeng Pang, Qingfeng Zhang, Haowen Yu, Jiahua Yang, Bo Zhou, Leyuan Zhang, Fuzheng Liu, Fenju |
author_sort | Huang, Jianfeng |
collection | PubMed |
description | INTRODUCTION: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. MATERIALS AND METHODS: 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide and clonogenic survival assays were done to evaluate the combined cytotoxic and radiosensitizing effects of nimotuzumab or celecoxib or the combination on CNE1 and CNE2 cells. Western blot analysis was performed to identify the effect of nimotuzumab and/or celecoxib with or without irradiation on the cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. RESULTS: Our results demonstrated that concurrent administration of nimotuzumab and celecoxib cooperatively enhanced the cytotoxicity and radiosensitivity of CNE2 cells but not CNE1 cells. The combination of both drugs with or without irradiation also cooperatively inhibited cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. CONCLUSION: Our results suggest a promising approach for the treatment of poorly differentiated NPC. |
format | Online Article Text |
id | pubmed-6052925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60529252018-07-23 Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells Huang, Jianfeng Yuan, Xiaopeng Pang, Qingfeng Zhang, Haowen Yu, Jiahua Yang, Bo Zhou, Leyuan Zhang, Fuzheng Liu, Fenju Drug Des Devel Ther Original Research INTRODUCTION: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. MATERIALS AND METHODS: 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide and clonogenic survival assays were done to evaluate the combined cytotoxic and radiosensitizing effects of nimotuzumab or celecoxib or the combination on CNE1 and CNE2 cells. Western blot analysis was performed to identify the effect of nimotuzumab and/or celecoxib with or without irradiation on the cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. RESULTS: Our results demonstrated that concurrent administration of nimotuzumab and celecoxib cooperatively enhanced the cytotoxicity and radiosensitivity of CNE2 cells but not CNE1 cells. The combination of both drugs with or without irradiation also cooperatively inhibited cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. CONCLUSION: Our results suggest a promising approach for the treatment of poorly differentiated NPC. Dove Medical Press 2018-07-16 /pmc/articles/PMC6052925/ /pubmed/30038488 http://dx.doi.org/10.2147/DDDT.S163595 Text en © 2018 Huang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Huang, Jianfeng Yuan, Xiaopeng Pang, Qingfeng Zhang, Haowen Yu, Jiahua Yang, Bo Zhou, Leyuan Zhang, Fuzheng Liu, Fenju Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells |
title | Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells |
title_full | Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells |
title_fullStr | Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells |
title_full_unstemmed | Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells |
title_short | Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells |
title_sort | radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052925/ https://www.ncbi.nlm.nih.gov/pubmed/30038488 http://dx.doi.org/10.2147/DDDT.S163595 |
work_keys_str_mv | AT huangjianfeng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT yuanxiaopeng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT pangqingfeng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT zhanghaowen radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT yujiahua radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT yangbo radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT zhouleyuan radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT zhangfuzheng radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells AT liufenju radiosensitivityenhancementbycombinedtreatmentofnimotuzumabandcelecoxibonnasopharyngealcarcinomacells |